Angiotensinogen gene silencing predicts bevacizumab response in recurrent glioblastoma patients

Medicin og biovidenskab

• Angiotensinogen 100%
• Bevacizumab 86%
• Gene Silencing 82%
• Glioblastoma 76%
• Methylation 37%
• Gene Expression 17%
• Genetic Promoter Regions 11%
• Combination Drug Therapy 6%
• DNA Methylation 5%
• Nonparametric Statistics 5%
• High-Throughput Nucleotide Sequencing 5%
• Regression Analysis 3%
• Therapeutics 3%
• Logistic Models 3%
• Biomarkers 3%
• Neoplasms 3%
• Quality of Life 3%
• Survival 3%